PDCD1 and cancer: The FDA-approved Ipilimumab (anti-CTLA4), Nivolumab, and Pembrolizumab (anti-PD1) monoclonal antibodies are able to unleash the antitumor immune response in cancer patients, showing unprecedented responses in aggressive tumors [23].